Welcome to our dedicated page for Ptc Therapeutics SEC filings (Ticker: PTCT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
PTC Therapeutics filings document a Delaware biopharmaceutical company with common stock listed on the Nasdaq Global Select Market under PTCT. Its Form 8-K reports cover quarterly and annual financial results, Regulation FD disclosures, product and pipeline updates, FDA-related communications, and board or compensation matters.
Proxy materials describe annual meeting governance, director elections, executive compensation, equity awards and related shareholder matters. The filing record also includes disclosures tied to rare-disease programs such as Sephience™ (sepiapterin), votoplam and Translarna™ (ataluren), along with the company’s capital structure and public-company reporting obligations.
Reporting person submitted a Form 144 notice to sell Common stock under Rule 144. The filing lists a planned sale of 2,464 shares on 07/09/2026 in connection with a Stock Option Exercise and multiple reported dispositions by Neil G. Almstead on 06/22/2026 through 07/07/2026 with individual sale amounts shown.
PTC Therapeutics executive Mark Elliott Boulding reported both sales and option exercises in PTC THERAPEUTICS, INC. common stock. On July 6, 2026, he sold 5,079 shares in a series of open‑market transactions at weighted average prices spanning $82.76 to $86.73. These sales were executed under a written Rule 10b5‑1 trading plan adopted on September 10, 2025.
On the same date, he exercised stock options to acquire 5,039 shares at strike prices of $46.54 and $39.42. Following the transactions, Boulding directly owns 105,272 shares of PTC Therapeutics common stock, and the filing shows remaining stock options outstanding in multiple series.
PTC Therapeutics chief technical operations officer Neil Gregory Almstead sold 46,774 shares of common stock in open-market trades while exercising stock options. The sales on July 6–7 were executed under a pre-set Rule 10b5-1 trading plan.
Almstead exercised options to acquire 46,774 shares at exercise prices of $38.10 and $39.42 per share, then sold equivalent amounts at weighted average prices in the mid‑$80s to high‑$80s. Following these transactions, he holds 60,299 shares directly and 2,899 shares indirectly through his spouse.
PTCT submitted a Form 144 notice reporting the proposed sale of 24,613 shares of Common Stock in connection with a Stock Option Exercise dated 07/07/2026. The filing lists Fidelity Brokerage Services LLC as the selling broker and indicates cash as the method.
The filing also discloses recent sales by Neil G. Almstead: 23,749 shares on 06/22/2026, 5,323 shares on 06/24/2026, 20,960 shares on 06/25/2026, 8,130 shares on 06/26/2026, and 22,161 shares on 07/06/2026. The filing is a Rule 144 notice of resale transactions.
PTCT notice reports restricted/common shares sold under Rule 144 and a stock option exercise converted to common stock on 07/06/2026. The filing lists multiple dispositions by Neil G. Almstead in June 2026 with specific share counts and aggregate sale proceeds shown.
PTCT affiliate submitted a Form 144 reporting proposed sales of Common Stock by an affiliate and several recent dispositions. The filing lists a planned sale tied to a Stock Option Exercise on 07/06/2026 and multiple sales by Mark Boulding on 04/06/2026, 05/08/2026, 05/15/2026, and 06/17/2026.
The excerpt shows specific share counts and dollar amounts for those transactions, including 2,265 shares for $157,282.96 on 04/06/2026 and 10,522 shares for $827,607.27 on 06/17/2026.
PTC Therapeutics chief technical operations officer Neil Gregory Almstead reported an options exercise and pre-planned share sale. He exercised stock options to acquire 8,130 shares of common stock at an exercise price of $38.10 per share and sold 8,130 shares in open-market transactions at weighted average prices in the mid-$85 range, pursuant to a Rule 10b5-1 trading plan adopted on November 11, 2025. Following these transactions, he holds 60,137 shares of PTC Therapeutics common stock directly and 2,737 shares indirectly through his spouse.
PTC Therapeutics, Inc. chief technical operations officer Neil Gregory Almstead reported a series of option exercises and share sales in PTCT common stock. On June 24–25, 2026, he exercised stock options for a total of 26,283 shares at exercise prices including $38.10 and $39.42 per share.
Over the same two days, he sold 26,283 shares of common stock in open-market transactions at prices generally in the mid‑$80s, with individual sale prices such as $87.00 and weighted‑average prices around $85–$86 per share. Following these transactions, Almstead directly holds 60,137 shares of PTCT common stock.
The filing notes that these transactions were carried out under a written Rule 10b5-1 trading plan adopted on November 11, 2025, indicating they were pre‑scheduled rather than timed discretionarily.
PTCT affiliate submitted a Form 144 providing notice of a proposed sale of 8,130 shares of Common Stock via a stock option exercise dated 06/26/2026. The filing also lists multiple sales by Neil G. Almstead in the past three months, including 52,003, 23,749, 5,323, and 20,960 shares on the dates shown.